新股消息 | 海纳医药递表港交所 业务涵盖药物发现、CMC、临床前和临床开发等全链条环节
智通财经网·2025-11-09 11:07

Company Overview - Haina Pharmaceutical is an integrated company engaged in drug research and manufacturing, providing CXO services and possessing proprietary product pipelines for commercialization through technology transfer [3][4] - The company ranks second in China for the total number of approved clinical trials and marketing licenses among CXO service providers [3] - Haina operates one of the most comprehensive CXO platforms in the industry, covering the entire drug development process from discovery to commercialization [3] Proprietary Pipeline and Technology Transfer - Haina has signed 67 drug technology transfer agreements during the reporting period, with notable projects including Omeprazole Sodium Bicarbonate Suspension and Dexamethasone Injection [4] - The company operates eight technology platforms that span drug chemistry research, complex formulation development, and GMP-scale production [4] Financial Performance - Revenue increased from RMB 264.73 million in 2022 to RMB 409.65 million in 2023, and is projected to reach RMB 424.59 million in 2024 [5][6] - Despite growth in proprietary pipeline revenue, total revenue for the six months ending June 30, 2025, is expected to decline to RMB 178 million from RMB 214.30 million in the same period of 2024 [6] - The gross profit margin has decreased from 60.1% in 2022 to 50.3% in 2023, with a slight recovery to 52.1% in the first half of 2025 [8][9] Industry Overview - The global pharmaceutical market is projected to grow from USD 1.542 trillion in 2024 to USD 2.527 trillion by 2034, with a CAGR of 5.1% [9] - The Chinese pharmaceutical market is expected to reach RMB 1.6297 trillion in 2024, growing to RMB 2.8863 trillion by 2034, with a CAGR of 5.9% [9] - The CRO service market in China is anticipated to grow from RMB 52.2 billion in 2020 to RMB 87.8 billion in 2024, with a CAGR of 13.9% [15] - The small molecule CMO/CDMO service market is projected to expand from RMB 22.6 billion in 2020 to RMB 60 billion in 2024, with a CAGR of 27.6% [18]